Medicaid

Pharmalot

Pharmalittle: House moves bill to thwart Medicaid misclassifications; McDonald’s to cut antibiotic use in beef

By Ed Silverman

CVS Miami
Pharmalot

Pennsylvania auditor recommends new laws to crack down on PBM contracts for Medicaid

By Ed Silverman

Pharmalot

Pharmalittle: Takeda shareholders approve Shire deal; HPV vaccine program in Quebec divides experts

By Ed Silverman

Pharmalot

Justice Department tells Supreme Court it wants to scuttle a whistleblower case against Gilead

By Ed Silverman

Pharmalot

Pharmalittle: Glaxo buys Tesaro for $5.1 billion; showdown as Takeda deal for Shire nears

By Ed Silverman

Pharmalot

Pharmalittle: Novartis pricing is being tested; Trump team looks to relax kickback rules

By Ed Silverman

Pharmalot

Pharmalittle: FDA still has concerns about compounders; Takeda bid for Shire wins advisory backing

By Ed Silverman

Kaleo Naloxone Donation 02
Pharmalot

A drug maker boosted the price of its opioid-overdose antidote by 600 percent, and taxpayers suffered

By Ed Silverman

Pharmalot

HHS watchdog chastises Mallinckrodt over a giveaway program for its pricey Acthar Gel drug

By Ed Silverman

Pharmalot

Pharmalittle: Novartis denies plan to spin off Sandoz; next House E&C chair eyes Medicare price negotiations

By Ed Silverman

Politics

In Michigan, Medicaid can now pay for drugs based on how well they work

By Ike Swetlitz

Pharmalot

Pharmalittle: Lawmakers pressed on drug-cost pledges; Walmart and Home Depot embrace co-pay accumulators

By Ed Silverman

Hep C San Fran
Pharmalot

Fewer state Medicaid programs restrict access to hep C meds, but some hurdles still exist

By Ed Silverman

Midterms results illo
Politics

Election rundown: How voters cast their ballots on health care issues and candidates

By Andrew Joseph

Montana Medicaid
First Opinion

Voters should seize the opportunity to expand Medicaid

By Rod Hochman

Pharmalot

AbbVie and Abbott pay $25 million to resolve claims of illegally marketing a cholesterol pill

By Ed Silverman

Trump drug prices
The Pharmalot View

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

By Ed Silverman

Pharmalot
Pharmalot

Ohio Medicaid examines a curious PBM relationship. Do other states have a similar issue?

By Ed Silverman

AmerisourceBergen
Pharmalot

AmerisourceBergen pays $625 million to settle allegations of illegally distributing drugs

By Ed Silverman

Gilead
Pharmalot

Looking to bolster dwindling hepatitis C sales, Gilead plans to sell generic versions

By Ed Silverman

Pfizer Allergan
Pharmalot

Doctor claims hospital fired him for complaining about ‘unethical’ ties to Allergan

By Ed Silverman

Abilify-MyCite illustration
Pharma

At $1,650 per month, the first digital pill will soon roll out to certain Medicaid patients with mental illness

By Rebecca Robbins

Pharmacy Benefit Managers illustration
Politics

The Trump administration can’t decide whether drug industry middlemen are the enemy — or part of the solution

By Ike Swetlitz

Pharmalot

Pharmalittle: More turnover at Gilead Sciences; EMA scales back its transparency policy

By Ed Silverman

Laura Dolph
Politics

Tapered to zero: In radical move, Oregon’s Medicaid program weighs cutting off chronic pain patients from opioids

By Lev Facher

CVS/Aetna
Pharmalot

Ohio Medicaid cancels contracts with two big PBMs over ‘spread’ pricing

By Ed Silverman

Charlie Baker
Pharmalot

To lower state drug costs, the National Governors Association is promoting several ideas

By Ed Silverman

HHS Secretary Alex Azar
Politics

HHS takes aim at drug companies for an ‘abusive behavior’ in Medicaid

By Ike Swetlitz

Hepatitis C
Pharmalot

Louisiana explores a ‘Netflix’ subscription model for buying hepatitis C drugs

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy